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Abstract: We studied non-response rates to antibiotics in the under-reported subgroup of adolescents
aged 12 to 17 years old, using standardised criteria representing antibiotic treatment failure.
Routine, primary care data from the UK Clinical Practice Research Datalink (CPRD) were used.
Annual, non-response rates by antibiotics and by indication were determined. We identified
824,651 monotherapies in 415,468 adolescents: 368,900 (45%) episodes for upper respiratory tract
infections (URTIs), 89,558 (11%) for lower respiratory tract infections (LRTIs), 286,969 (35%) for
skin/soft tissue infections (SSTIs) and 79,224 (10%) for acute otitis media (AOM). The most frequently
prescribed antibiotics were amoxicillin (27%), penicillin-V (24%), erythromycin (11%), flucloxacillin
(11%) and oxytetracycline (6%). In 1991, the overall non-response rate was 9.3%: 11.9% for
LRTIs, 9.5% for URTIs, 7.1% for SSTIs, 9.7% for AOM. In 2012, the overall non-response rate
was 9.2%. Highest non-response rates were for AOM in 1991–1999 and for LRTIs in 2000–2012.
Physicians generally prescribed antibiotics to adolescents according to recommendations. Evidence of
antibiotic non-response was less common among adolescents during this 22-year study period
compared with an all-age population, where the overall non-response rate was 12%.
Keywords: otitis media; adolescents; primary care; first line; respiratory tract infection; skin infection;
treatment response; treatment failure; antibiotics
1. Introduction
Microbial resistance in adults and children is increasing worldwide, posing a major threat to
public health [1]. Numerous strains of bacteria are becoming more difficult and time-consuming
to treat [2], and now some infections cannot be treated with antibiotics [3]. Nevertheless, general
practitioners (GPs) are thought to rarely report antibiotic resistance and believe that the problem is out
of their control [4].
In order to address non-response to antibiotic treatment, it is essential that patterns of
non-response are understood. Microbial resistance typically affects hospitalised patients, more so than
in primary care settings, although antibiotics are routinely prescribed for respiratory tract infections
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in both primary and secondary care [5]. Considering the wide range of antibiotics available, and
the different types of microbial infections, the impact of antibiotic resistance has proven difficult
to characterise [6]. Extensive prescribing of antibiotics is considered to be the cause of high levels
of antibiotic resistance and corresponding treatment non-response [7]. In adolescents, there is a
high possibility of improper and over-prescribing of antibiotics, particularly when the prevalence of
respiratory tract infections and acute otitis media (AOM) is high [8]. Children with acute respiratory
tract infections treated with penicillin had reported resistance levels to be as high as 52% [9].
Nevertheless, data characterising antibiotic resistance in this younger age group are limited.
Concern regarding the effectiveness of antibiotics in adolescents has emerged. During clinical
development, this age group is often studied less thoroughly than children aged 12 years and younger.
Failure to respond to antibiotics does not necessarily imply a causal association with antibiotic
resistance [10]. Many patients who are prescribed antibiotics in primary care are unlikely to benefit
because they are suffering from viral infections. Nevertheless, information about non-response trends
is important, as this may help clinicians share information with their patients about potential harm
and benefits.
In our previous study [11] marking the 25th anniversary of the availability of clarithromycin, we
reported that antibiotic treatment non-response rates for four common infection classes in primary
care increased by 12% from 1991 to 2012. Here, given the emerging concern regarding the effectiveness
of antibiotics in adolescents, our existing real-world data set was re-analysed to evaluate antibiotic
non-response rates in the adolescent age group and compared these with the original study cohort,
which contained patients of all ages.
2. Methods
2.1. Data Source
Data were extracted from the Clinical Practice Research Datalink (CPRD), a longitudinal
anonymised research database drawn from nearly 700 primary care practices in the UK. This database
contains demographic, diagnostic, treatment and referral information for approximately 8% of the UK
population [12].
The data used in this study was a subgroup of the dataset from our recent study [11] and consisted
of patients aged from 12 to 17 years that received prescriptions for antibiotics.
The current study received ethical approval from CPRD’s Independent Scientific Advisory
Committee on 31 October 2013, protocol number 13_168R.
2.2. Classification of Infection
Prescriptions for antibiotics were selected for four relevant infection classes: upper respiratory
tract infections (URTIs), which included tonsillitis, laryngitis, pharyngitis and sinusitis; lower
respiratory tract infections (LRTIs), including pneumonia, whooping cough and bronchitis; skin
and soft tissue infections (SSTIs), including acne, abscesses, impetigo and cellulitis; and acute otitis
media (AOM). These categories were the same as in our previous study [11]. The index date was set as
the date of initiation of antibiotic monotherapy. Figure 1 illustrates selection of study data.
2.3. Identification of Antibiotic Treatments
Antibiotic monotherapy episodes were defined here as one or more consecutive prescriptions for
a single antibiotic separated by no more than 30 days and uninterrupted by prescriptions for other
antibiotic drug substances. Only first-line monotherapies, i.e. where there were no prescriptions for a
different antibiotic in the 30 days prior to initiation, were included in this study. Monotherapy episodes
were excluded if they began before 1991 or after 2012, or if the interval from the later of the patient’s
registration date and the practice’s up-to-standard date to initiation was less than 365 days.
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Figure 1. Data flow diagram for selection of antibiotic monotherapies in adolescents reported in the 
Clinical Practice Research Datalink. 
2.4. Infection Rates and Antibiotic Prescription over Time 
In a separate procedure (not illustrated), we measured background infection rates over time for 
each infection class as the proportion of all GP consultations in which the GP recorded a diagnosis of 
that infection in adolescents. Additionally, we determined the proportion of these infection-related 
consultations in which an antibiotic was prescribed. The prescription pattern of the five most 
commonly prescribed antibiotics over the research period in each infection is presented.  
2.5. Antibiotic Treatment Non-Response Rates 
For each year of the studied period, we evaluated the proportion of antibiotic monotherapies 
that resulted in treatment non-response. We defined antibiotic treatment non-response as the earliest 
occurrence of any of five events: (1) prescription of a different antibiotic within 30 days of the initial 
antibiotic prescription; or (2) GP record of admission to hospital with a diagnosis of infection within 
30 days of initial antibiotic prescription; or (3) GP referral to an infection-related specialist service 
within 30 days of initial antibiotic prescription; or (4) a GP record of emergency department visit 
within three days of antibiotic initiation; or (5) a GP record of death with an infection-related clinical 
code, within 30 days of initial antibiotic prescription. 
Treatment non-response rates are presented overall and for the five most frequently prescribed 
antibiotics within each infection class. Over the 22 years observed, the number of patients and 
participating practices increased, requiring treatment non-response rates to be averaged over the first 
five-year period (1991–1995) in order to create a more stable baseline for comparison with those in 
the last five-year period (2008–2012). 
2.6. Statistical Analysis  
Treatment non-response rates were presented as standardised ratios of observed rates to 
predicted rates for each year, using 1991 as the index year. Standardised ratios were adopted because 
of variations in antibiotic prescription patterns and age dispersion. Indexed treatment non-response 
rates were calculated using a matrix of infection subclass, antibiotic drug and gender; rates from 1991 
were used to predict expected number of treatment non-responses, and, subsequently, to calculate 
the ratio. 
  
Figure 1. Data flow diagram for selection of antibiotic monotherapies in adolescents reported in the
Clinical Practice Research Datalink.
2.4. Infection Rates and Antibiotic Prescription over Time
In a separate procedure (not illustrated), we measured background infection rates over time for
each infection class as the proportion of all GP consultations in which the GP recorded a diagnosis of
that infection in adolescents. Additionally, we determined the proportion of these infection-related
consultations in which an antibiotic was prescribed. The prescription pattern of the five most commonly
prescribed antibiotics over the research period in each infection is presented.
2.5. Antibiotic Treatment Non-Response Rates
For each year of the studied period, we evaluated the proportion of antibiotic monotherapies
that resulted in treatment non-response. e defined antibiotic treatment non-response as the earliest
oc ur ence of any of five events: (1) prescription of a dif erent antibiotic within 30 days of the initial
antibiotic prescription; or (2) GP record of admis ion to hospital with a diagnosis of infection within
30 days of initial antibiotic prescription; or (3) GP refer al to an infection-related specialist service
within 30 days of initial antibiotic prescription; or (4) a GP record of emergency department visit
within thre days of antibiotic initiation; or (5) a GP record of death with an infection-related clinical
code, within 30 days of initial antibiotic prescription.
Treatment non-response rates are presented overal and for the five most frequently prescribed
antibiotics within each infection clas . t 22 years observe , the nu ber of patients and
participating practices increased, requiring treatment non-response rates to be averaged over the first
five-year period (19 1–19 5) in order to create a more stable baseline for c mparison with those in the
last five-year period (2008–2 12).
2.6. Statistical Analysis
Treatment non-response rates were presented as standardised ratios of observed rates to predicted
rates for each year, using 1991 as the index year. Standardised ratios were adopted because of variations
in antibiotic prescription patterns and age dispersion. Indexed treatment non-response rates were
calculated using a matrix of infection subclass, antibiotic drug and gender; rates from 1991 were used
to predict expected number of treat ent non-responses, and, subsequently, to calculate the ratio.
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3. Results
In this study 824,651 antibiotic monotherapies were prescribed to 415,468 adolescents. Of these,
368,900 (45%) therapies were for URTIs; 89,558 (11%) for LRTIs; 286,969 (35%) for SSTIs; and
79,224 (10%) for AOM (Figure 1).
3.1. Baseline Characteristics
The mean age of the adolescents in 1991–1995 was 14.5 years (Standard deviation (SD) 1.7 years)
and in 2008–2012, 14.8 years (SD 1.7 years) (Table 1). Those with a diagnosis of AOM were younger
(1991–1995: 13.9, SD 1.6 years and 2008–2012: 14.1, SD 1.7 years) and those with SSTIs slightly older
(1991–1995: 15.1, SD 1.5 years and 2008–2012: 15.1, SD 1.5 years). Gender distribution was generally
comparable across infection classes (1991–1995: 49.9% female; 2008–2012: 53.0% female), although
URTIs were more common in females (1991–1995: 54.1%; 2008–2012: 58.7%) and LRTIs more common
in males (1991–1995: 53.8%; 2008–2012: 53.1%).
Within the LRTI infection class, the proportion of co-medications increased from 1991–1995 to
2008–2012 from 2.8% to 8.0% for systemic corticosteroids, 22.3% to 29.4% for bronchodilators and 9.8%
to 16.3% for inhaled corticosteroids. The proportion of co-medications in the other three infection
classes remained generally constant from the first to the latter five-year period. The proportion of
adolescent smokers was high (20%–27%) in the 1991–1995 period, but decreased to 5%–12% in the
period 2008–2012 (Table 1).
3.2. Consultation Rates
GP consultation rates for the four infection classes, with or without antibiotic treatment,
decreased over time (Figure 2). The all-cause consultation rate decreased from 466 consultations
per 1000 registered patients per year in 1991 to 284 in 2012, a decrease of 39.1% (p < 0.01). The change
in consultation rates varied by type of infection. Rates of consultations per 1000 patients per year
decreased from 251 to 110 (p < 0.01) for URTIs, from 46 to 16 (p < 0.01) for AOM, and from 50 to
20 (p < 0.01) for LRTIs. Consultation rates for SSTI increased from 129 to 137 consultations per
1000 patients per year (p < 0.01).
3.3. Most Commonly Prescribed Antibiotics in Adolescents
The five most frequently prescribed antibiotics were amoxicillin (27.3%), penicillin-V (24.2%),
erythromycin (11.3%), flucloxacillin (10.5%) and oxytetracycline (5.9%). Lymecycline (4.1%),
co-amoxiclav (1.5%), doxycycline (1.4%) and clarithromycin (1.3%) were less frequently prescribed;
the remaining antibiotics were prescribed in even lower quantities and they are reported together in a
combined group termed “Others” (12.5%).
The prescription pattern of the most frequently prescribed antibiotics in each infection class, for
each year between 1991 and 2012 is illustrated in Figure 3. For URTIs, penicillin-V (53.6%) was the
most commonly prescribed antibiotic over the whole period. Amoxicillin was the most frequently
prescribed antibiotic for the treatment of LRTIs (73.3%) and AOM (75.8%). The five most commonly
prescribed antibiotics for SSTIs were flucloxacillin (30.4%), oxytetracycline (17.0%), erythromycin
(15.3%), lymecycline (11.8%) and doxycycline (4.0%). In this infection class, the combined group of
other antibiotics accounted for up to 21% of prescriptions.
In adolescents, skin and soft tissue infection prescriptions were more prominent than in the
original, all-age study (35% vs. 23%), with therapies associated with acne comprising more than half of
the antibiotic therapies in the adolescent study [11]. By contrast, antibiotic therapy for lower respiratory
infection was relatively rare compared with the overall study (11% vs. 29%). Antibiotic therapies
for upper respiratory infections and acute otitis media occurred in proportions comparable with the
original study (45% vs. 39%, and 10% vs. 9%, respectively).
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Table 1. Baseline characteristics by infection class and by early and late time period.
Baseline Characteristic
Upper Respiratory Lower Respiratory Skin and Soft Tissue Acute Otitis Media Overall
1991–1995 2008–2012 1991–1995 2008–2012 1991–1995 2008–2012 1991–1995 2008–2012 1991–1995 2008–2012
No of patients, n 32,150 73,528 10,063 20,259 13,768 66,937 8614 18,179 50,157 151,200
Antibiotic monotherapies, n 52,830 99,726 13,258 23,529 22,566 100,719 10,917 20,714 99,571 244,688
Male, n (%) 14,745 (45.9%) 30,354 (41.3%) 5411 (53.8%) 10,754 (53.1%) 7635 (55.5%) 33,426 (49.9%) 4309 (50.0%) 8510 (46.8%) 25,151 (50.1%) 71,113 (47.0%)
Female, n (%) 17,405 (54.1%) 43,174 (58.7%) 4652 (46.2%) 9505 (46.9%) 6133 (44.5%) 33,511 (50.1%) 4305 (50.0%) 9669 (53.2%) 25,006 (49.9%) 80,087 (53.0%)
Age, years, mean (SD) 14.4 (1.7) 14.7 (1.7) 14.4 (1.7) 14.6 (1.7) 15.1 (1.5) 15.1 (1.5) 13.9 (1.6) 14.1 (1.7) 14.5 (1.7) 14.8 (1.7)
Smoking, n (%):
Never or not known 24,285 (46.0%) 63,936 (64.1%) 6032 (45.5%) 15,446 (65.6%) 11,216 (49.7%) 71,795 (71.3%) 4841 (44.3%) 12,127 (58.5%) 46,374 (46.6%) 163,304 (66.7%)
Ex–smoker 1575 (3.0%) 1085 (1.1%) 467 (3.5%) 277 (1.2%) 634 (2.8%) 863 (0.9%) 318 (2.9%) 120 (0.6%) 2994 (3.0%) 2345 (0.9%)
Current 12,918 (24.5%) 8646 (8.7%) 3520 (26.6%) 2645 (11.2%) 4481 (19.9%) 5044 (5.0%) 2445 (22.4%) 1085 (5.2%) 23,364 (23.5%) 17,420 (7.1%)
BMI, kg¨ m´2, mean (SD) 21.7 (4.4) 23.0 (5.5) 21.5 (4.6) 22.8 (5.6) 21.6 (3.9) 22.9 (5.2) 21.5 (4.7) 23.3 (6.1) 21.6 (4.4) 22.9 (5.4)
Blood pressure, mmHg, mean (SD):
Systolic 112.3 (12.3) 111.8 (12.4) 112.2 (13.0) 112.0 (12.7) 113.8 (12.4) 112.6 (12.5) 111.9 (13.6) 111.6 (12.7) 112.6 (12.6) 112.1 (12.5)
Diastolic 69.0 (8.8) 68.1 (8.7) 68.7 (8.6) 68.2 (9.1) 69.6 (8.5) 68.1 (8.6) 68.2 (8.9) 68.1 (9.1) 69.0 (8.7) 68.1 (8.7)
Co–medications, n (%):
Systemic corticosteroid 201 (0.4%) 932 (0.9%) 370 (2.8%) 1881 (8.0%) 63 (0.3%) 348 (0.3%) 40 (0.4%) 97 (0.5%) 674 (0.6%) 3258 (1.3%)
Bronchodilator 3181 (6.0%) 7058 (7.1%) 2,951 (22.3%) 6917 (29.4%) 856 (3.8%) 3963 (3.9%) 551 (5.0%) 1138 (5.5%) 7539 (7.6%) 19,076 (7.8%)
Inhaled corticosteroid 1673 (3.2%) 4444 (4.5%) 1296 (9.8%) 3840 (16.3%) 418 (1.9%) 2560 (2.5%) 334 (3.1%) 758 (3.7%) 3721 (3.7%) 11,602 (4.7%)
n = number, SD = standard deviation.
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Figure 2. Consultation rates for the selected infection classes, proportion of infections in the selected classes treated with an antibiotic, antibiotic treatment non-
response rates by infection class, and adjusted and indexed treatment non-response rates (indexed to 1991 = 100, and adjusted for age, sex, and type of antibiotic 
treatment used) observed between 1991 and 2012. 
Figure 2. Consultation rates for the selected infection classes, proportion of infections in the selected classes treated with an antibiotic, antibiotic treatment non-response
rates by infection class, and adjusted and indexed treatment non-response rates (indexed to 1991 = 100, and adjusted for age, sex, and type of antibiotic treatment
used) observed between 1991 and 2012.
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Figure 3. Five most commonly prescribed antibiotics between 1991 and 2012 by selected infection 
class. 
A consistent prescription rate over the 22 years was generally observed in the five most 
frequently prescribed antibiotics for URTIs. However, antibiotics prescribed for SSTIs showed a 
varying pattern over time (Figure 3). For example, lymecycline showed the greatest increase in 
therapies since it was introduced in 1996, increasing from 0.1% to 27.9%. The proportion of 
oxytetracycline therapies showed the greatest decrease: from 23.6% to 10.0%. 
The most frequently prescribed antibiotics in each infection class remained the same from the 
first five-year period to the last five-year period, albeit with changes in their ranking of relative 
frequency (Table 2). Penicillin-V remained the most prescribed antibiotic for the treatment of URTIs 
in the first and last five-year periods. For LRTIs and AOM, the most frequently prescribed antibiotic 
in both five-year periods was amoxicillin. In the first five-year period, oxytetracycline was the second-
most-prescribed antibiotic for the treatment of SSTIs in adolescents. 
Table 2. Average antibiotic therapy and treatment non-response rates (%) by infection class and by 
early and late time period with rank order in parentheses. 
Infection Site Antibiotic 
Therapy Rates Antibiotic Treatment Non-Response Rates
Average 
1991–1995 
Average
2008–2012 
Average
1991–1995 
Average 
2008–2012 
% (Rank 
Order) 
% (Rank Order) % (Rank Order) % (Rank Order) 
URTIs 
Penicillin-V 47.9 (1) 56.0 (1) 8.8% (2) 7.4% (1) 
Amoxicillin 25.6 (2) 26.8 (2) 9.7% (3) 9.0% (2) 
Others a 13.5 (3) 4.5 (4) 16.0% (6) 31.3% (6) 
Erythromycin 10.5 (4) 8.4 (3) 11.2% (4) 9.7% (3) 
Co-amoxiclav 2.0 (5) 1.5 (6) 12.7% (5) 16.2% (5) 
Clarithromycin 0.5 (6) 2.8 (5) 8.0% (1) 10.8% (4) 
LRTIs 
Amoxicillin 60.9 (1) 79.1 (1) 9.6% (2) 10.1% (1) 
Others b 22.3 (2) 4.5 (4) 17.2% (6) 37.4% (6) 
. Five most com only prescribed antibiot cs between 199 and 2012 by selected infect on lass.
A consistent prescription rate over the 22 years was generally observed in the five most frequently
prescribed antibiotics for URTIs. However, antibiotics prescribed for SSTIs showed a varying pattern
over time (Figure 3). For example, lymecycline showed the greatest increase in therapies since it was
introduced in 1996, increasing from 0.1% to 27.9%. The proportion of oxytetracycline therapies showed
the greatest decrease: from 23.6% to 10.0%.
The most frequently prescribed antibiotics in each infection class remained the same from the first
five-year period to the last five-year period, albeit with changes in their ranking of relative frequency
(Table 2). Penicillin-V remained the most prescribed antibiotic for the treatment of URTIs in the first and
last five-year periods. For LRTIs and AOM, the most frequently prescribed antibiotic in both five-year
periods was amoxicillin. In the first five-year period, oxytetracycline was the second-most-prescribed
antibiotic for the treatment of SSTIs in adolescents.
Table 2. Average antibiotic therapy and treatment non-response rates (%) by infection class and by
early and late time period with nk order in parentheses.
Infection Site Antibiotic
Therapy Rates Antibiotic Treatment Non-Response Rates
Average 1991–1995 Average 2008–2012 Average 1991–1995 Average 2008–2012
% (Rank Order) % (Rank Order) % (Rank Order) % (Rank Order)
URTIs
Penicillin-V 47.9 (1) 56.0 (1) 8.8% (2) 7.4% (1)
Amoxicillin 25.6 (2) 26.8 (2) 9.7% (3) 9.0% (2)
Others a 13.5 (3) 4.5 (4) 16.0% (6) 31.3% (6)
Erythromycin 10.5 (4) 8.4 (3) 11.2 (4) 9.7% (3)
Co-amoxiclav 2.0 (5) 1.5 (6) 12.7% (5) 16.2% (5)
Clarithromycin 0.5 (6) 2.8 (5) 8.0% (1) 10.8% (4)
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Table 2. Cont.
Infection Site Antibiotic
Therapy Rates Antibiotic Treatment Non-Response Rates
Average 1991–1995 Average 2008–2012 Average 1991–1995 Average 2008–2012
% (Rank Order) % (Rank Order) % (Rank Order) % (Rank Order)
LRTIs
Amoxicillin 60.9 (1) 79.1 (1) 9.6% (2) 10.1% (1)
Others b 22.3 (2) 4.5 (4) 17.2% (6) 37.4% (6)
Erythromycin 10.6 (3) 7.9 (2) 11.3% (3) 10.7% (2)
Co-amoxiclav 4.5 (4) 2.9 (5) 12.6% (4) 13.8% (4)
Clarithromycin 1.2 (5) 4.8 (3) 9.1% (1) 10.7% (3)
Doxycycline 0.5 (6) 0.9 (6) 17.0% (5) 16.0% (5)
SSTIs
Others c 40.4 (1) 13.0 (3) 8.6% (4) 15.9% (7)
Oxytetracycline 23.2 (2) 12.1 (5) 4.7% (1) 6.3% (2)
Flucloxacillin 16.6 (3) 32.4 (1) 9.9% (5) 9.0% (4)
Erythromycin 15.4 (4) 12.8 (4) 8.2% (3) 9.1% (5)
Doxycycline 4.2 (5) 4.6 (6) 6.6% (2) 6.7% (3)
Clarithromycin 0.2 (6) 1.3 (7) 18.2% (6) 12.7% (6)
Lymecycline - - 23.8 (2) - - 5.1% (1)
AOM
Amoxicillin 63.4 (1) 80.3 (1) 9.7% (1) 8.4% (1)
Others d 15.6 (2) 4.0 (4) 16.7% (6) 29.7% (5)
Erythromycin 7.9 (3) 7.5 (2) 12.8% (3) 10.1% (2)
Co-amoxiclav 7.6 (4) 4.5 (3) 12.8% (2) 13.6% (4)
Penicillin-V 5.0 (5) 1.2 (6) 16.2% (4) 33.1% (6)
Clarithromycin 0.5 (6) 2.5 (5) 16.3% (5) 10.7% (3)
AOM, acute otitis media; LRTIs, lower respiratory infections; SSTIs, soft and skin tissue infections; URTIs,
upper respiratory tract infections. a Others (URTIs): 19 antibiotics, of which the 10 most commonly
prescribed were doxycycline, trimethoprim, flucloxacillin, cefalexin, lymecycline, oxytetracycline, azithromycin,
cefaclor, nitrofurantoin, minocycline; b Others (LRTIs): 14 antibiotics (top 10: penicillin-V, cephalexin,
azithromycin, trimethoprim, flucloxacillin, oxytetracycline, lymecycline, cefaclor, ciprofloxacin, cefradine);
c Others (SSTIs): 18 antibiotics (top 10: amoxicillin, co-amoxiclav, minocycline, trimethoprim, penicillin-V,
tetracycline, co-fluampicil, cephalexin, ciprofloxacin, nitrofurantoin); d Others (AOM): 15 antibiotics (top 10:
flucloxacillin, cefalexin, trimethoprim, ciprofloxacin, doxycycline, lymecycline, oxytetracycline, cefaclor,
metronidazole, co-fluampicil).
3.4. Failure to Respond to Antibiotics in Adolescents
The overall antibiotic non-response rate for the four infection classes was 9.5%, with a non-linear
increase from 9.3% in 1991, peaking at 11.0% in 1995, and then declining to 9.2% in 2012. In 1991,
the treatment non-response rates were 11.9% for LRTIs, 9.5% for URTIs, 7.1% for SSTIs and 9.7% for
AOM. In 2012, treatment non-response rates were 11.4% for LRTIs, 9.4% for URTIs, 8.4% for SSTIs and
9.8% for AOM (Figure 2). SSTIs had the lowest treatment non-response rate in each five-year period
(7.8% in 1991–1995 and 8.6% in 2008–2012). The highest treatment non-response rates were for AOM
in 1991–1995 (11.7%) and for LRTIs from 2008 to 2012 (11.4%) (Table 2).
The two most frequently prescribed antibiotics for URTIs, penicillin-V and amoxicillin, both had
stable non-response rates, ranging from 7% to 11% over the study period (Figure 4). Within the five
most commonly prescribed antibiotics for LRTIs, amoxicillin, erythromycin and co-amoxiclav had
constant treatment non-response rates of between 5% and 17% over the period (Figure 4). The five
most frequently prescribed antibiotics for SSTIs had treatment non-response rates of between 4% and
13%, except for the antibiotic lymecycline, which only became available in 1996 (Figure 4).
For AOM, the treatment non-response rates of amoxicillin, erythromycin and co-amoxiclav
remained stable over time (Figure 4). In contrast, for penicillin-V, treatment non-response rates
increased markedly: from 16% in 1991–1995 to 33% in 2008–2012, with a rate of 40% in 2009 (Figure 4,
Table 2).
3.5. Adjusted Rates of Non-Response of Antibiotic Treatment
After adjusting for antibiotic, index year and infection class, the rate of LRTI treatment
non-response initially increased by 9% from 1991 to 1992 and then decreased from 1992 to 2012
by 28.3%. For SSTIs, URTIs and AOM, rates of antibiotic treatment non-response decreased from 1991
to 2012 by 40.5%, 10.2% and 19.6%, respectively. The overall adjusted treatment non-response rate
decreased by 21.5% over the study period (Figure 2).
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Figure 4. Antibiotic treatment non-response rates observed from 1991 to 2012 for the most commonly 
prescribed antibiotics in each selected infection class. “Other” antibiotics are defined in Table 2. 
4. Discussion 
This study examined non-response, in adolescents, to antibiotics prescribed for four common 
infection classes. We found that primary care physicians prescribe antibiotics to adolescents as they 
do for adults, rarely prescribing non-recommended compounds. In general, response to antibiotic 
treatment in adolescents was better than that in the all-age population. 
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were around 10%. Co-amoxiclav and the combined “Other” antibiotics had higher and increasing
treatment non-response rates. When prescribed for URTIs, penicillin and amoxicillin had lower
treatment non-response rates in adolescents, compared with the original cohort.
Lower respiratory tract infections were uncommon in adolescents (only 2.6% of the infections).
The antibiotics most frequently prescribed for lower respiratory tract infections: amoxicillin,
erythromycin, co-amoxiclav, clarithromycin and doxycycline, were also the most frequently prescribed
in the original cohort. Non-response rates for amoxicillin and the macrolides erythromycin and
clarithromycin in adolescents were stable and at or below 10% throughout the study period, whilst in
the original cohort, the respective non-response rates were between 15% and 20%, probably reflecting
the large proportion of older and frailer patients.
During the first five years of the study period, many different antibiotics were prescribed for the
treatment of skin infections in adolescence. Over time and with the introduction of lymecycline in the
UK in 1996, the pattern of prescription for this infection class became more defined, with flucloxacillin
and lymecycline together being prescribed in more than half of the cases.
In acute otitis media in adolescents, the top five antibiotics were amoxicillin, erythromycin,
co-amoxiclav, penicillin-V and clarithromycin. In these adolescents as well as in the original study
cohort, the majority of cases of AOM in the last five years of the study were treated with amoxicillin
(80%). Amoxicillin, erythromycin and clarithromycin had the lowest average treatment non-response
rates, between 8% and 11%, over the last five years of the study; these rates were lower than those
reported for the original cohort.
Most respiratory tract infections managed in UK primary care are viral in origin, therefore a large
proportion of the infections included in our study would not have responded to antibiotic treatment.
Surveillance linked to clinical findings and outcomes was not carried out on a systematic basis during
this time period in the UK. We do not therefore know whether changing pathogens and antibiotic
sensitivities could have accounted for in the trends described. Point-of-care tests are not used in UK
primary care for respiratory tract infections. The numbers consulting with coughs and colds as well as
the proportion of coughs and colds treated with antibiotics in primary care increased between 2004
and 2011 [15].
5. Limitations
The adolescents formed a small subgroup of the original, all-age population and they were not
excluded from the overall population values reported here. Had we compared the adolescent subgroup
with the original population minus adolescent patients, the comparisons might have been more distinct.
Differences observed here may therefore be somewhat underestimated but are still valid.
For infections requiring long-term antibiotic use, our algorithm may be overestimating rates of
non-response because the prescription of different antibiotics in ongoing therapy would have been
taken to signify non-response. Similarly, some infection episodes may have been misclassified as
non-responsive because the initial therapy was followed within 30 days by the prescription of another
antibiotic for a different indication.
6. Conclusions
Adolescents prescribed antibiotics are usually clinically managed as adults, and research on
antibiotic non-response in this age group is scarce. In this study, we evaluated antibiotic prescription
patterns and non-response rates for the treatment of four common infection classes in adolescents.
Our data suggest that primary care physicians prescribe antibiotics to adolescents in line with
current guidelines regarding initial prescriptions and, using our definition of antibiotic non-response,
that adolescents respond generally better to these antibiotics compared with the general population
as a whole. Non-response to antibiotics does not imply a causal link with antibiotic resistance,
as many of the infections for which antibiotics are prescribed are viral. However, antibiotic resistance
may be relevant in a minority of infections, and knowledge of non-response rates may be useful
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to inform discussion with patients about potential risks and benefits of antibiotic treatment for
common infections.
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